This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

Pipeline Overview

View by Therapeutic Area

View by Molecule Type

Pipeline movement since July 21, 2017

Pipeline data through
October 17, 2017

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase 3

Phase 2

  •
    BTK Inhibitor
    immunology
    LY3337641 (BTK inhibitor) is a new chemical entity that inhibits the Bruton's tyrosine kinase. LY3337641 is being studied for the treatment of rheumatoid arthritis.

    For more information on LY3337641 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Mirikizumab
    LY3074828 (formerly known as IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of immune diseases including ulcerative colitis and psoriasis.

    For more information on LY3074828 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Dual Amylin Calcitonin Receptor Agonist
    DACRA-042 is a new biologic entity that acts as a dual agonist of both the amylin receptor and calcitonin receptor and is being studied for the treatment of diabetes.

    For more information on DACRA-042 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • GIP/GLP-1 Co-Agonist Peptide
    LY3298176 (GIP/GLP-1 Co-agonist Peptide) is a new biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of diabetes.

    For more information on LY3298176 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • BACE Inhibitor
    LY3202626 (BACE Inhibitor), a chemical entity, is an oral beta secretase cleaving enzyme (BACE) inhibitor. LY3202626 is being studied for the treatment of Alzheimer's disease.

    For more information on LY3202626 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Merestinib cancer (mer es’ ti nib)
    LY2801653 (formerly known as c-Met inhibitor) is a chemical entity that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET, a receptor for hepatocyte growth factor. Preclinical testing also has shown LY2801653 to inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, and DDR1/2 and the serine/threonine kinases MKNK1/2. LY2801653 is being studied for the treatment of cancer.

    For more information on LY2801653 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PI3 Kinase/mTOR Dual Inhibitor
    LY3023414 (PI3 Kinase/mTOR dual Inhibitor) is a chemical entity being studied for development in combinations for the treatment of cancer.

    For more information on LY3023414 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Prexasertib (prex” a ser’ tib)
    LY2606368 monomesylate monohydrate (formerly known as Chk1 inhibitor) is a chemical entity that preferentially binds to and inhibits checkpoint kinase 1 (Chk1), a global regulator of the mammalian cell cycle and, to a lesser extent, inhibits Chk2. LY2606368 monomesylate monohydrate is being studied for the treatment of cancer.

    For more information on LY2606368 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    systemic lupus erythematosus
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of systemic lupus erythematosus.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    atopic dermatitis
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of atopic dermatitis.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Dulaglutide Investigational Doses
    LY2189265 (dulaglutide), a glucagon-like peptide-1 analog, is a biologic entity being studied at investigational doses as a once-weekly treatment for type 2 diabetes.

    For more information on LY2189265 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Abemaciclib (a be muh sī klib)
    LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of pancreatic cancer.

    For more information on LY2835219 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Abemaciclib (a be muh sī klib)
    LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of squamous NSCLC.

    For more information on LY2835219 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase 1

Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of October 17, 2017. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.

Property of Eli Lilly and Company.

Legend

New Molecule
Molecule That Achieved Milestone
Nonproprietary Name Granted
Molecule Moved to Earlier Phase
Lost Through Attrition
Regulatory Approval Achieved
*Commercial Collaboration
  • Select NME
  • Select NILEX
  • Diagnostic
GTM-PQNKVL